# Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

> **NCT02996214** · PHASE4 · UNKNOWN · sponsor: **Nanjing Luye Sike Pharmaceutical Co., Ltd.** · enrollment: 536 (estimated)

## Conditions studied

- Squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Paclitaxel Liposome
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02996214
- **Lead sponsor:** Nanjing Luye Sike Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2019-12
- **Final completion:** 2020-06
- **Target enrollment:** 536 (ESTIMATED)
- **Last updated:** 2020-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02996214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02996214, "Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02996214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*